SecSonar.com

Veracyte, Inc. (VCYT)

Veracyte, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Veracyte, Inc. (VCYT) is a Biotechnology company based in US with a market capitalization of $3.8B. Revenue grew 16.0% year-over-year and the company generated $126.6M in free cash flow. This page tracks VCYT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 824 employees · IPO Oct 30, 2013

Valuation

Valuation & price

$38.48 · as of May 17, 2026 · -36.4% vs 52w high

46.7

P/E ratio

Latest-FY diluted EPS

2.88

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$60.49$41.76$23.03Jul 25Dec 25Jul 26Jul 7, 25$26.34Jul 9, 25$27.08Jul 11, 25$27.08Jul 15, 25$25.24Jul 17, 25$24.22Jul 21, 25$23.03Jul 23, 25$24.21Jul 25, 25$25.25Jul 29, 25$24.47Jul 31, 25$23.51Aug 4, 25$24.32Aug 6, 25$23.97Aug 11, 25$27.99Aug 13, 25$30.68Aug 15, 25$30.22Aug 19, 25$29.57Aug 21, 25$29.43Aug 25, 25$29.55Aug 27, 25$28.61Aug 29, 25$30.34Sep 3, 25$30.62Sep 5, 25$32.43Sep 9, 25$31.99Sep 11, 25$31.86Sep 16, 25$32.28Sep 18, 25$33.23Sep 22, 25$33.93Sep 24, 25$32.68Sep 26, 25$33.44Sep 30, 25$34.33Oct 2, 25$35.63Oct 6, 25$36.04Oct 8, 25$35.10Oct 10, 25$34.80Oct 14, 25$33.95Oct 16, 25$35.81Oct 21, 25$36.10Oct 23, 25$35.64Oct 27, 25$35.97Oct 29, 25$35.41Oct 31, 25$36.08Nov 4, 25$36.12Nov 6, 25$41.69Nov 10, 25$42.35Nov 12, 25$42.30Nov 14, 25$39.35Nov 18, 25$38.76Nov 20, 25$40.85Nov 25, 25$49.38Nov 28, 25$47.34Dec 2, 25$46.16Dec 4, 25$47.41Dec 8, 25$44.36Dec 10, 25$43.33Dec 12, 25$42.84Dec 16, 25$43.22Dec 18, 25$42.04Dec 22, 25$43.09Dec 24, 25$42.77Dec 29, 25$42.88Jan 2, 26$42.39Jan 6, 26$45.64Jan 8, 26$43.56Jan 12, 26$43.45Jan 14, 26$42.45Jan 16, 26$41.57Jan 21, 26$43.30Jan 23, 26$42.27Jan 27, 26$39.80Jan 29, 26$38.74Feb 2, 26$38.16Feb 4, 26$36.10Feb 9, 26$36.73Feb 11, 26$35.99Feb 13, 26$35.77Feb 18, 26$36.61Feb 20, 26$35.63Feb 24, 26$35.69Feb 26, 26$38.75Mar 2, 26$36.01Mar 4, 26$36.27Mar 6, 26$33.85Mar 10, 26$32.78Mar 12, 26$30.93Mar 17, 26$33.48Mar 19, 26$32.78Mar 23, 26$33.54Mar 25, 26$32.79Mar 27, 26$30.01Mar 31, 26$32.21Apr 2, 26$32.25Apr 7, 26$32.15Apr 9, 26$31.35Apr 13, 26$32.44Apr 15, 26$34.04Apr 17, 26$33.80Apr 22, 26$33.71Apr 24, 26$34.33Apr 28, 26$33.43Apr 30, 26$32.92May 4, 26$33.45May 6, 26$41.19May 8, 26$40.42May 12, 26$39.56May 14, 26$38.90May 18, 26$41.50May 20, 26$45.19May 22, 26$45.03May 28, 26$47.99Jun 1, 26$48.18Jun 3, 26$48.69Jun 5, 26$48.73Jun 9, 26$49.24Jun 11, 26$47.42Jun 15, 26$49.15Jun 17, 26$51.29Jun 22, 26$53.19Jun 24, 26$56.76Jun 26, 26$60.49Jul 2, 26$57.08
$23.0352-week range$60.49
Loading valuation history…

Fundamentals

Key fundamentals

$3.8B

Market cap

16.0%

Revenue growth (YoY)

69.6%

Gross margin

$126.6M

Free cash flow (USD)

-$373.2M

Net debt

Net cash position

2.8%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$65.1MFY 2017$72.0MFY 2018$92.0MFY 2019$120.4MFY 2020$117.5MFY 2021$219.5MFY 2022$296.5MFY 2023$361.1MFY 2024$445.8MFY 2025$517.1M
$65.1M$517.1M

Free cash flow by year

2016 → 2025

FY 2016$-32.2MFY 2017$-25.7MFY 2018$-15.4MFY 2019$-6.0MFY 2020$-12.5MFY 2021$-37.0MFY 2022$-1.0MFY 2023$34.3MFY 2024$63.8MFY 2025$126.6M
-$32.2M$126.6M

Gross margin by year

2021 → 2025

FY 202166.1%FY 202265.7%FY 202368.7%FY 202466.9%FY 202569.6%
66.1%69.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

8

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $197K · 10b5-1 PlanEASTHAM KARIN · Director · $197.2KJun 22, 2026Filing
  • 8-K eventEquity Incentive Plan AmendedJun 11, 2026Filing
  • Insider sellInsider Sell $700K · 10b5-1 PlanLeite John · Global Chief Commercial Off · $699.7KJun 4, 2026Filing
  • Insider sellInsider Sell $6.9M · 10b5-1 PlanStapley Marc · Director, Chief Executive Officer · $6.9MJun 4, 2026Filing
  • Insider sellInsider Sell $177K · 10b5-1 PlanChambers Rebecca · Chief Financial Officer · $177.1KJun 4, 2026Filing
  • Insider sellInsider Sell $158K · 10b5-1 PlanMcGuire Annie · EVP, General Counsel · $158KJun 4, 2026Filing
  • Insider sellInsider Sell $1.1MWygant Jonathan · VP, Chief Accounting Officer · $1.1MMay 27, 2026Filing
  • Insider sellInsider Sell $440K · 10b5-1 PlanEPSTEIN ROBERT S · Director · $440.1KMay 22, 2026Filing
  • Insider sellInsider Sell $398K · 10b5-1 PlanMcGuire Annie · SVP, General Counsel · $398.2KMay 8, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing

Questions

Frequently asked questions

What is Veracyte, Inc.'s market cap?

Veracyte, Inc. (VCYT) has a market capitalization of $3.8B.

What is VCYT's P/E ratio?

VCYT trades at a price-to-earnings ratio of 46.7, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is VCYT's price-to-book (P/B) ratio?

VCYT trades at 2.88 times book value per share.

Are insiders buying VCYT stock?

SEC Form 4 filings show no open-market insider buys at Veracyte, Inc. in the last 90 days (8 sells).

Same arena

Related companies in Biotechnology

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

DNTH

Dianthus Therapeutics, Inc.

$3.8B

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

NAMS

NewAmsterdam Pharma Company N.V.

$3.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.